News Posts List
Semafore Pharmaceuticals Presents New Clinical Data on Novel Prodrug Dual PI3K-mTOR Inhibitor in B-Cell Malignancies and Solid Tumors
06/22/2010
Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.
Cambridge scientists identify new class of cancer gene
06/22/2010
Cambridge scientists have discovered a new class of cancer gene, occupying the central control position of gene activity and acting to keep cells from turning cancerous.
Friends rally around Livingston police officer battling cancer
06/22/2010
When things go bump in the night, Sgt. Scott Paske has been one of the first people on the scene to help Livingston residents. Now the Polk County community is reaching out to help the Livingston Police Officer battle kidney cancer.
Single Institutional Experience With Nephron-sparing Surgery For Pathologic Stage T3bNxM0 Renal Cell Carcinoma Confined To The Renal Vein
06/22/2010
Our study of nephron-sparing surgery in renal cell carcinoma (RCC) invading the segmental branches of the renal vein is consistent with the trend towards increased utilization of "partial nephrectomy" during surgical management of RCC.
Thank you, Francie, for your care
06/22/2010
Ten years ago, the board of Bickelhaupt Arboretum asked Francie Hill if she would come back to her hometown of Clinton, Iowa, and help run the 14-acre outdoor plant museum her parents had founded.
Bill Bro Named To Renal Cancer Task Force
06/21/2010
Kidney Cancer Association CEO Bill Bro has accepted an invitation from the National Cancer Institute (NCI) to join the currently forming Renal Cancer Task Force (RCTF). The RCTF is a part of NCI's Genitourinary Steering Committee (GUSC). The GUSC and other organ system based steering committees were formed as part of NCI's effort to enhance its clinical trials enterprise.
Exelixis Regains Full Rights to Develop and Commercialize XL184
06/21/2010
XL184 is an investigational oral inhibitor of MET, VEGFR2, and RET that produces antiangiogenic, antiproliferative, and antiinvasive effects in preclinical tumor models. MET is mutationally activated in some tumor types, such as hereditary and sporadic papillary renal cell carcinoma and some head and neck cancers.
AVEO Pharmaceuticals Granted Patents For Diagnostic Tests To Identify Patient Populations Likely To Respond To Tivozanib Treatment
06/21/2010
These patents cover two different diagnostic tests for identifying human patients likely to respond to treatment with tivozanib, AVEO's highly potent and selective inhibitor of VEGF receptors 1, 2 and 3, which is currently being evaluated in a global Phase 3 clinical trial, TIVO-1, in patients with renal cell cancer (RCC).
Meet Old Friends And Make New Ones In Our Cyber Café
06/21/2010
This is an easy way to chat in real-time with family and friends, whenever you want to get together. No login is required. Please remember that chats are public. Use the "Share This" links (above) to spread the word that you're online.
Nature Reviews Urology - Focus On Kidney Cancer
06/21/2010
Available free online until July 7, 2010. No-cost registration is required.
News Feed